Sivut

Kommentit (1748)

jussipussi
Seuraa 
Viestejä53596

"Cost effectiveness of vitamin c supplementation for pregnant smokers to improve offspring lung function at birth and reduce childhood wheeze/asthma.

Abstract

OBJECTIVE:

To determine the implications of supplemental vitamin C for pregnant tobacco smokers and its effects on the prevalence of pediatric asthma, asthma-related mortality, and associated costs.

STUDY DESIGN:

A decision-analytic model built via TreeAge compared the outcome of asthma in a theoretical annual cohort of 480,000 children born to pregnant smokers through 18 years of life. Vitamin C supplementation (500 mg/day) with a standard prenatal vitamin was compared to a prenatal vitamin (60 mg/day). Model inputs were derived from the literature. Deterministic and probabilistic sensitivity analyses assessed the impact of assumptions.

RESULT:

Additional vitamin C during pregnancy would prevent 1637 cases of asthma at the age of 18 per birth cohort of pregnant smokers. Vitamin C would reduce asthma-related childhood deaths and save $31,420,800 in societal costs over 18 years per birth cohort.

CONCLUSION:

Vitamin C supplementation in pregnant smokers is a safe and inexpensive intervention that may reduce the economic burden of pediatric asthma."

https://www.ncbi.nlm.nih.gov/pubmed/29785060 .

jussipussi
Seuraa 
Viestejä53596

"Dietary intake and blood concentrations of antioxidants and the risk of cardiovascular disease, total cancer, and all-cause mortality: a systematic review and dose-response meta-analysis of prospective studies.

RESULTS:

Sixty-nine prospective studies (99 publications) were included. The summary RR per 100-mg/d increment of dietary vitamin C intake was 0.88 (95% CI: 0.79, 0.98, I2 = 65%, n = 11) for coronary heart disease,

0.92 (95% CI: 0.87, 0.98, I2 = 68%, n = 12) for stroke,

0.89 (95% CI: 0.85, 0.94, I2 = 27%, n = 10) for cardiovascular disease,

0.93 (95% CI: 0.87, 0.99, I2 = 46%, n = 8) for total cancer,

and 0.89 (95% CI: 0.85, 0.94, I2 = 80%, n = 14) for all-cause mortality.

Corresponding RRs per 50-μmol/L increase in blood concentrations of vitamin C were

0.74 (95% CI: 0.65, 0.83, I2 = 0%, n = 4),

0.70 (95% CI: 0.61, 0.81, I2 = 0%, n = 4),

0.76 (95% CI: 0.65, 0.87, I2 = 56%, n = 6),

0.74 (95% CI: 0.66, 0.82, I2 = 0%, n = 5),

and 0.72 (95% CI: 0.66, 0.79, I2 = 0%, n = 8).

Dietary intake and/or blood concentrations of carotenoids (total, β-carotene, α-carotene, β-cryptoxanthin, lycopene) and α-tocopherol, but not dietary vitamin E, were similarly inversely associated with coronary heart disease, stroke, cardiovascular disease, cancer, and/or all-cause mortality.

CONCLUSIONS:

Higher dietary intake and/or blood concentrations of vitamin C, carotenoids, and α-tocopherol (as markers of fruit and vegetable intake) were associated with reduced risk of cardiovascular disease, total cancer, and all-cause mortality. These results support recommendations to increase fruit and vegetable intake, but not antioxidant supplement use, for chronic disease prevention."

https://www.ncbi.nlm.nih.gov/pubmed/30475962 .

Sisältö jatkuu mainoksen alla
Sisältö jatkuu mainoksen alla
jussipussi
Seuraa 
Viestejä53596

Efficacy of vitamin C for the prevention and treatment of upper respiratory tract infection. A meta-analysis in children.

Abstract

PURPOSE:

Upper respiratory tract infection (URTI) is a common infection in children, generally caused by viral respiratory infection. Vitamin C is currently proposed as prophylaxis for URTI. The purpose of this study was to assess the effectiveness of vitamin C administration in children for the prevention and reduced duration of URTI through a systematic literature review.

METHODS:

Review of the literature conducted between October 2017 and January 2018 in the main medical databases (CENTRAL, Medline and Embase) and by a gray literature approach. The selection criteria were: double-blind randomized controlled trials (RCTs) comparing vitamin C use to placebo in children aged 3 months to 18 years without chronic infection. Efficacy was assessed in terms of incidence, duration and severity of symptoms of URTI. A meta-analysis was conducted where possible.

RESULTS:

Eight RCTs, including 3135 children aged 3 months to 18 years, were selected. Quantitative analysis showed no difference between vitamin C administration and placebo (odds ratio = 0.75, 95% CI [0.54-1.03], p = 0.07, I2 = 74%). Vitamin C administration was found to decrease the duration of URTI by 1.6 days (standardized mean differences = -0.30 [-0.53; -0.08], p = 0.009, I2 = 70%). Children under 6 years of age benefit from more effective vitamin C supplementation associated with echinacea. No serious adverse events were reported.

CONCLUSIONS:

Although no preventive effects were found, vitamin C intake reduced the duration of URTI. Considering the frequency of URTI, the inappropriate prescription of antibiotics, and the safe nature of vitamin C, its supplementation is justified, especially in children under 6 years of age and those who present a high frequency of URTI. There is a sound rationale for further trials with greater statistical power among children of this age."

https://www.ncbi.nlm.nih.gov/pubmed/30465062 .

jussipussi
Seuraa 
Viestejä53596

jussipussi kirjoitti:
"Cost effectiveness of vitamin c supplementation for pregnant smokers to improve offspring lung function at birth and reduce childhood wheeze/asthma.

https://www.ncbi.nlm.nih.gov/pubmed/29785060 .

Vitamin C may reduce the harm done to lungs in infants born to mothers who smoke during their pregnancy, according to a randomized, controlled trial published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

In "Oral Vitamin C (500 mg/day) to Pregnant Smokers Improves Infant Airway Function at 3 Months: A Randomized Trial," Cindy T. McEvoy, MD, MCR, and her co-authors report that at three months of age, the infants whose mothers took 500 mg of vitamin C in addition to their prenatal vitamin had significantly better forced expiratory flows (FEFs). FEFs measure how fast air can be exhaled from the lung and are an important measure of lung function because they can detect airway obstruction.

The researchers also discovered an association between the infant FEFs and a genetic variant some of the mothers possessed that appeared to amplify the negative impact of nicotine on the babies before they were born. Other studies have linked this genetic factor, specifically for the α5 nicotinic acetylcholine receptor, to increased risk of lung cancer and obstructive lung disease.

...Summing up the findings of the current study, Dr. McEvoy said that a relatively low dosage of vitamin C may present "a safe and inexpensive intervention that has the potential to help lung health of millions of infants worldwide."

However, she added, helping mothers quit smoking should remain the primary goal for health professionals and public health officials. "Although vitamin C supplementation may protect to some extent the lungs of babies born to mothers who smoke during pregnancy, those children will still be at greater risk for obesity, behavioral disorders and other serious health issues," she said.2

https://medicalxpress.com/news/2018-12-vitamin-infants-lungs-pregnancy.html .

jussipussi
Seuraa 
Viestejä53596

[quote=jussipussi

"C-vitamiini hoitaa sydäntä"

https://www.tiede.fi/artikkeli/uutiset/c-vitamiini-hoitaa-sydanta .[/quote]Tämä olisi ollut hyvä myös mainita artikkelissa.

"Effect of vitamin C on endothelial function in health and disease: a systematic review and meta-analysis of randomised controlled trials.

Abstract

BACKGROUND:

Observational studies indicate that higher vitamin C intake is associated with reduced risk for cardiovascular diseases. However, randomised controlled trials (RCT) examining the effect of vitamin C on endothelial function (EF) have reported inconsistent results. The aims of this systematic review and meta-analysis were to determine the effect of vitamin C supplementation on EF and to investigate whether the effect was influenced by health status, study duration, dose and route of vitamin C administration.

.....CONCLUSIONS:

Vitamin C supplementation improved EF. The effect of vitamin C supplementation appeared to be dependent on health status, with stronger effects in those at higher cardiovascular disease risk."

https://www.ncbi.nlm.nih.gov/pubmed/24792921 .

.

"Effect of vitamin C and vitamin E supplementation on endothelial function: a systematic review and meta-analysis of randomised controlled trials.

.....Significant improvements in EF were observed in trials supplementing with vitamin C alone (500-2000 mg/d) (SMD: 0·25, 95% CI 0·02, 0·49, P=0·043) and vitamin E alone (300-1800 IU/d; 1 IU vitamin E=0·67 mg natural vitamin E) (SMD: 0·48, 95% CI 0·23, 0·72, P=0·0001), whereas co-administration of both vitamins was ineffective (vitamin C: 500-2000 mg/d; vitamin E: 400-1200 IU/d) (SMD: 0·12, 95% CI-0·18, 0·42, P=0·428). The effect of vitamin C supplementation on EF increased significantly with age (β 0·023, 95% CI 0·001, 0·05, P=0·042). There was a significant negative correlation between baseline plasma vitamin E concentration and the effect of vitamin E supplementation on EF (β-0·03, 95% CI-0·06, -0·001, P=0·029). Supplementation with either vitamin C or vitamin E alone improves EF. However, subgroup analysis emphasises the importance of careful characterisation and selection of a population group which may benefit from such supplementation."

https://www.ncbi.nlm.nih.gov/pubmed/25919436 .

"Endoteeli

Endoteeli on yksikerroksinen epiteeli. Se verhoaa sydämessä, veri- ja imusuonissa niiden sisäpintaa. Endoteeli koostuu endoteelisoluista.[1]"

https://fi.wikipedia.org/wiki/Endoteeli .

jussipussi
Seuraa 
Viestejä53596

jussipussi kirjoitti:
[quote=jussipussi

"C-vitamiini hoitaa sydäntä"

https://www.tiede.fi/artikkeli/uutiset/c-vitamiini-hoitaa-sydanta .

Tämä olisi ollut hyvä myös mainita artikkelissa.

"Effect of vitamin C on endothelial function in health and disease: a systematic review and meta-analysis of randomised controlled trials.

Abstract

BACKGROUND:

Observational studies indicate that higher vitamin C intake is associated with reduced risk for cardiovascular diseases. However, randomised controlled trials (RCT) examining the effect of vitamin C on endothelial function (EF) have reported inconsistent results. The aims of this systematic review and meta-analysis were to determine the effect of vitamin C supplementation on EF and to investigate whether the effect was influenced by health status, study duration, dose and route of vitamin C administration.

.....CONCLUSIONS:

Vitamin C supplementation improved EF. The effect of vitamin C supplementation appeared to be dependent on health status, with stronger effects in those at higher cardiovascular disease risk."

https://www.ncbi.nlm.nih.gov/pubmed/24792921 .

.

"Effect of vitamin C and vitamin E supplementation on endothelial function: a systematic review and meta-analysis of randomised controlled trials.

.....Significant improvements in EF were observed in trials supplementing with vitamin C alone (500-2000 mg/d) (SMD: 0·25, 95% CI 0·02, 0·49, P=0·043) and vitamin E alone (300-1800 IU/d; 1 IU vitamin E=0·67 mg natural vitamin E) (SMD: 0·48, 95% CI 0·23, 0·72, P=0·0001), whereas co-administration of both vitamins was ineffective (vitamin C: 500-2000 mg/d; vitamin E: 400-1200 IU/d) (SMD: 0·12, 95% CI-0·18, 0·42, P=0·428). The effect of vitamin C supplementation on EF increased significantly with age (β 0·023, 95% CI 0·001, 0·05, P=0·042). There was a significant negative correlation between baseline plasma vitamin E concentration and the effect of vitamin E supplementation on EF (β-0·03, 95% CI-0·06, -0·001, P=0·029). Supplementation with either vitamin C or vitamin E alone improves EF. However, subgroup analysis emphasises the importance of careful characterisation and selection of a population group which may benefit from such supplementation."

https://www.ncbi.nlm.nih.gov/pubmed/25919436 .

"Endoteeli

Endoteeli on yksikerroksinen epiteeli. Se verhoaa sydämessä, veri- ja imusuonissa niiden sisäpintaa. Endoteeli koostuu endoteelisoluista.[1]"

https://fi.wikipedia.org/wiki/Endoteeli .[/quote]Jos muistan oikein niin ihmisessä on verisuoniston endoteelia pinta-alaltaan yhteelaskettuna noin jallkapallokentän kokoinen ala.

jussipussi
Seuraa 
Viestejä53596

jussipussi kirjoitti:
jussipussi kirjoitti:
Suonensiäisesti annosteltu C on itsessään hyvin mielenkiintoinen aihe. Myrkytys, bakteeri ja viruskompikaatiot mahdollisina tutkimuskohteina.
High Dose Intraveneous Vitamin C and Chikungunya Fever: A Case Report. Abstract
The Chikungunya (CHIKV) fever is a viral disease produced by a single-stranded RNA Alphavirus from the Togaviridae genus. Its transmission occurs only through mosquito vectors, principally Aedes aegypti. It requires a human-mosquito-human transmission cycle. It is associated with severe arthritis/arthralgias, myalgias, high fever, headache, and maculopapular rash. Joint ache appears to be symmetrical. The virus has an incubation period of 2 to 7 days, where the high fever is typically presented. It is followed by arthralgias and myalgias, and rashes, which last for 3 to 5 days. However, the arthralgias can persist for months after the infection, which can contribute to severe arthritis. As of now, no vaccine exists for the virus and no official treatment has been developed aside from standard procedures of the use of acetaminophen (paracetamol), and non-steroidal anti-inflammatory drugs. This is a case report of a 54-year old Hispanic individual that reported left shoulder pain, left knee pain and fever. The symptoms started on a Saturday in September 2014 in middle of the night. The patient was treated with high doses of intravenous vitamin C over two days. The symptoms resolved after the infusions without any side effects. Based on the positive outcome in this case, we propose that intravenous vitamin C should be studied further as a potential treatment for acute viral infections.

"A simple vitamin cocktail to treat sepsis has shaken up the medical world, raising hopes of a more effective treatment for one of history’s great killers. But will it stand up to tougher tests?

Researchers at several hospitals around the world are trying to reproduce the success reported by a critical-care doctor in Virginia in beating back sepsis, one of the leading causes of hospital deaths.

The results got a lot of attention. But it was a small study, comparing before-and-after patient outcomes. Now, researchers are gearing up to test the therapy with large-scale trials using patients selected at random, with some given the cocktail and others given a placebo.

Survival often depends on an immediate dose of antibiotics and intravenous fluids, along with tests to look for signs of an infection or organ failure. Estimates of how much it costs to treat sepsis approach $24 billion a year.

Jarone Lee, MD, medical director of the intensive care unit at Massachusetts General Hospital, says finding a good treatment for sepsis would solve a lot of health care problems. ­

But it’s too early to declare victory without better data, says Lee, who is not involved in the ongoing trials.

“What I think we’re looking for is essentially hard science and great science about how this will work,” he says. “It doesn’t even have to show the amazing results like Paul did, just that we’re moving the needle forward and decreasing mortality or some other process measure that improves outcomes.”

Ambitious studies planned

Sevransky’s study plans to involve at least 500 and up to 2,000 patients at multiple hospitals for about a year and a half. The plan is to wrap up work in December 2019.

A second study, led by Michael Donnino, MD, at Harvard’s Beth Israel Deaconess Medical Center, involves about 200 patients and  a wider number of hospitals. It is expected to end in a year, says Ari Moskowitz, MD, a pulmonary care and critical care specialist at Beth Israel Deaconess.

Moskowitz says they hope the vitamin cocktail will  help limit injury to organs, such as the kidneys or heart. The study will evaluate how well it prevents organ injury along with survival rates. “Saving lives is the ultimate goal of the intervention,” he says.

Similar studies are underway in New Jersey, Slovenia, China, Australia, and Qatar.

The dose being studied is about 1.5 grams intravenously, every 6 hours for 4 days -- several times higher than people get from ordinary vitamin supplements or eating fruit, but less than some patients get while having chemotherapy, he said.

In a follow-up paper in April, Marik wrote that vitamin C lowers oxidative stress and inflammation, and it helps stop blood vessels from dilating, which helps maintain blood pressure. People who have sepsis often don't have enough vitamins C and B1, and those vitamins appear to combine with the steroid hydrocortisone to boost the effects.

“There is in fact an enormous amount of basic science to support this,” he says. An Australian study found that if Marik’s mixture works, it could shave more than 40% off the long-term cost of treating the disease.

“The bottom line is it saves billions of dollars and millions of life-years, and at worst, if it doesn’t work, all it does is waste a little bit of money and nothing is lost,” he says.

Sevransky says previous research has suggested vitamin C can improve blood flow to tissues in the body of a sepsis patient, keeping the cells supplied with nutrients and oxygen and preventing organ failure."

https://www.webmd.com/drug-medication/news/20180521/vitamin-cocktail-for... .

"Vitamin C therapy linked to better survival rates after sepsis

New research led by Virginia Commonwealth University and published in the October issue of the Journal of the American Medical Association suggests that patients with sepsis and septic lung injury could have a better chance of survival and recover more quickly when treated with vitamin C infusions.

Sepsis, a bodywide inflammation in response to infection, is a leading cause of death in U.S. hospitals, with up to 300,000 deaths reported each year, according to the National Institute of General Medical Sciences.

Researchers discovered that intravenous vitamin C therapy reduced mortality in septic patients from 46% in the placebo group to almost 30% in the vitamin C group at day 28.

"This therapy could potentially transform the way we care for sepsis patients. We may have found a lifesaving therapy," said first author Alpha A. "Berry" Fowler III, M.D., a professor in the Division of Pulmonary Disease and Critical Care Medicine in the Department of Internal Medicine at the VCU School of Medicine. "While further research is needed, the results from our preliminary study are encouraging.""

https://www.sciencedaily.com/releases/2019/10/191001110838.htm .

Sivut

Suosituimmat

Uusimmat

Sisältö jatkuu mainoksen alla

Uusimmat

Suosituimmat